Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
An exploratory, multicenter, randomized, placebo-controlled, double blind, dose escalation
study comparing a standard therapy for submassive pulmonary embolism (Enoxaparin sodium) to a
combined therapy of Drotrecogin alfa (activated) plus Enoxaparin sodium.